ClearRead Bone Suppression (formerly SoftView)

February 21, 2012 - If you are looking for a particular object -- say a yellow pencil -- on a cluttered desk, how does your brain work to visually locate it?

For the first time, a team led by Carnegie Mellon University (CMU) neuroscientists has identified how different neural regions communicate to determine what to visually pay attention to and what to ignore. This finding is a major discovery for visual cognition and will guide future research into visual and attention deficit disorders.

March 1, 2012 ? Visage Imaging Inc. announced today it has released Visage 7.1, the latest version of the Visage® 7 enterprise imaging platform. Visage 7’s innovative, thin-client, server-side processing technology has been enhanced with new features providing usability, performance and enterprise-wide administration improvements.

March 6, 2012 – Accelitech and partners have just completed a transaction to bring the first and only
CyberKnife stereotactic radiosurgery system to the Republic of Ireland. Scheduled to begin treating
patients in fall of 2012, the center will open on the campus of the Hermitage Medical Clinic in Dublin.

March 12, 2012 —Fujifilm Medical Systems U.S.A. Inc. announced the commercial availability of the FDR D-EVO portable upgrade system, the company’s first digital radiography (DR) upgrade option for analog mobile portables.

FDR D-EVO portable upgrade system

March 12, 2012 — A new study shows that the use of gadobenate dimeglumine, the highest relaxivity gadolinium-based contrast agent (GBCA) available for central nervous system (CNS) magnetic resonance imaging (MRI), over a high concentration MRI contrast agent may improve clinicians’ ability to visualize lesions of the brain.

March 12, 2012 — Siemens Healthcare announced shipment of the Acuson S1000 ultrasound system, a premium ultrasound platform. The Acuson S1000 system expands access to imaging performance at a very low cost of ownership.

March 12, 2012 — Varian Medical Systems received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for a surface beacon transponder to be used with the Calypso system as a tracking device capable of monitoring motion during radiotherapy treatments for indications anywhere in the body.

Subscribe Now